Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
-
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
-
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
-
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
-
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
-
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
-
Plus Therapeutics Announces New Employment Inducement Grants
-
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
-
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024